Bird & Bird (Brussels)

Anne Federle

Bird & Bird (Brussels)
Lawyer (Partner)

Anne is a partner in Bird & Bird’s Competition & EU Law Group and shares her time between the Brussels and Düsseldorf offices. Anne has very substantial experience in German, EU and international merger control and has been involved in a large number of complex Phase 2 cases before the European Commission and the German Federal Cartel Office. She regularly advises clients in abuse and cartel proceedings and in internal cartel investigations. Her practice also covers advising on the competition law aspects of cooperation, distribution and license agreements. Anne’s expertise spans a number of sectors, including automotive, electronics, telecommunications, healthcare, post and logistics, food and beverages, and energy.

Auteurs associés

Bird & Bird (Budapest)
Bird & Bird (Brussels)
Bird & Bird (Dusseldorf)
Bird & Bird (Dusseldorf)


383 Bulletin

Pauline Van Sande, Anne Federle The EU Commission opens in-depth investigation into the proposed acquisition of a producer of wearable tech devices by a Big tech on the basis that it would entrench the latter’s market position in the online advertising market (Fitbit / Google)


At the beginning of August, the European Commission opened an in-depth investigation into the acquisition of Fitbit by Google. The transaction was notified to the Commission on 15 June 2020 and Google proposed commitments to address the Commission’s preliminary concerns on 13 July 2020. (...)

Daniel Arányi, Anne Federle The EU Commission recognises the impact of the COVID-19 across Europe’s trade and issues a temporary framework for State aid measures to support the economy


Public safety measures, supply disruptions and the unprecedented dramatic decline in automotive markets as a result of the COVID-19 outbreak have forced OEMs to stop production in numerous Member States. Such decisions will of course have far-reaching direct and indirect effects on businesses (...)

Anne Federle, Pauline Van Sande The EU Court of Justice clarifies when patent settlement agreements restricting a generic pharmaceutical company’s ability to enter the market, infringe EU antitrust rules (Generics - UK)


Article summary : Settlement Agreements Can Be Anti-Competitive Only If The Involved Companies Are (At Least) Potential Competitors. A Careful Examination Must Determine Whether A Generic Manufacturer Would Have Entered Into The Market Without A "Pay Per Delay" Agreement. The Classification (...)

548 Revue

Envoyer un message